Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with -Mutated Colorectal Cancer.

mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in -mutated cells, and is synergistic with irinotecan. A dose escalation trial of FOLFIRI/bevacizumab [irinotecan (150-180 mg/m) and pelareorep (1 × 10 TCID-3 × 10 TCID)] was implemented in adult patients with oxaliplatin refractory/intolerant, -mutant mCRC.